GENENTA SCIENCE S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.914 USD | +14.28% |
|
-25.57% | -41.13% |
| Apr. 08 | Genenta Science S.P.A. Announces Resignation of Board Members | CI |
| Mar. 29 | Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 49.56M 53.13M |
|---|---|---|---|---|---|
| Net income 2024 * | -15M -16.08M | Net income 2025 * | -18M -19.3M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.73
x | P/E ratio 2025 * |
-3.44
x | Employees | 14 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.75% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +14.28% | ||
| 1 week | -25.57% | ||
| Current month | -16.74% | ||
| 1 month | -25.89% | ||
| 3 months | -27.33% | ||
| 6 months | -44.91% | ||
| Current year | -41.13% |
1 week
2.20
3.97
1 month
2.203.97
Current year
2.204.96
1 year
2.206.81
3 years
2.2013.13
5 years
2.2013.13
10 years
2.2013.13
| Managers | Title | Age | Since |
|---|---|---|---|
Bernhard Gentner
FOU | Founder | - | 14-07-23 |
Luigi Naldini
FOU | Founder | - | 14-07-23 |
| Founder | 50 | 14-07-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Sirgo
CHM | Chairman | 70 | 22-04-30 |
Anthony Marucci
BRD | Director/Board Member | 62 | 21-05-19 |
Roger Abravanel
BRD | Director/Board Member | 77 | 21-05-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 2.914 | +14.28% | 11,459 |
| 24-04-24 | 2.55 | -29.75% | 62,693 |
| 24-04-23 | 3.63 | -8.02% | 679 |
| 24-04-22 | 3.947 | +1.17% | 1,251 |
| 24-04-19 | 3.901 | -0.37% | 6,415 |
Delayed Quote Nasdaq, April 25, 2024 at 04:30 pm EDT
More quotes
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.72
EUR
Average target price
21.37
EUR
Spread / Average Target
+685.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.13% | 46.45M | |
| +1.12% | 43.84B | |
| +6.77% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +6.01% | 25.53B | |
| -24.92% | 18.18B | |
| -3.63% | 12.29B | |
| +27.16% | 12.29B | |
| +7.30% | 11.15B |
- Stock Market
- Equities
- GNTA Stock
